- Home
- AKTX
as 07-26-2024 4:00pm EST
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
| Founded: | N/A | Country: | United Kingdom |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 37.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 19.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $5.50 | Next Earning Date: | 05-16-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Akari Therapeutics plc ADS News
AKTX Breaking Stock News: Dive into AKTX Ticker-Specific Updates for Smart Investing
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
GlobeNewswire
2 months ago
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
GlobeNewswire
2 months ago
LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
GlobeNewswire
2 months ago
The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
GlobeNewswire
2 months ago
Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Compare AKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKTX Akari Therapeutics plc ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.